<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Katsoulidou, A</style></author><author><style face="normal" font="default" size="100%">Manesis, E.</style></author><author><style face="normal" font="default" size="100%">Rokka, C</style></author><author><style face="normal" font="default" size="100%">Issaris, C.</style></author><author><style face="normal" font="default" size="100%">Pagoni, A.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D</style></title><secondary-title><style face="normal" font="default" size="100%">J Viral HepatJ Viral HepatJ Viral Hepat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of viral hepatitis</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of viral hepatitisJournal of viral hepatitis</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Monitoring/methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis D, Chronic/*virology</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis Delta Virus/genetics/*isolation &amp; purification</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction/*methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style  face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction/methods</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Viral/genetics/*isolation &amp; purification</style></keyword><keyword><style  face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Load/*methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">256-62</style></pages><isbn><style face="normal" font="default" size="100%">1365-2893 (Electronic)1352-0504 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Hepatitis delta virus (HDV) infection is a usually severe type of viral hepatitis associated with increased mortality and rapid evolution to cirrhosis. Currently, treatment is limited to extended interferon administration and measurement of HDV RNA blood levels is essential to judge the response. The aim of this study was to develop a highly sensitive and reproducible real-time reverse transcriptase-polymerase chain reaction (real-time RT-PCR) for the quantitation of circulating HDV RNA of all clades (1-8), and assess its usefulness in the follow-up of patients. The amplification was combined with molecular beacon technology using the LightCycler 2.0 system. The assay was specific and showed linearity over a wide range from 13 to 13 x 10(10) copies/mL. The 95% detection limit was 43.2 copies/mL. Intra-assay reproducibility, as expressed by the coefficient of variation, ranged from 1.84 to 18.61%, whereas the corresponding estimates for the inter-assay variability ranged from 0.57 to 10.18%. Finally, the dynamic profiles of six patients regarding virological (HDV RNA, HBV DNA), biochemical and serological data were constructed. We were able to observe that most patients who were treated with an interferon-based regime showed a significant reduction in delta viremia. In conclusion, our real-time RT-PCR for HDV RNA quantification combines high sensitivity and reproducibility in a high dynamic range, can provide important information for patient management and can be a useful tool for monitoring the response to antiviral therapies.</style></abstract><accession-num><style face="normal" font="default" size="100%">23490370</style></accession-num><notes><style face="normal" font="default" size="100%">Katsoulidou, AManesis, ERokka, CIssaris, CPagoni, ASypsa, VHatzakis, AengCase ReportsEvaluation StudyResearch Support, Non-U.S. Gov'tEngland2013/03/16 06:00J Viral Hepat. 2013 Apr;20(4):256-62. doi: 10.1111/jvh.12000. Epub 2012 Sep 13.</style></notes><auth-address><style face="normal" font="default" size="100%">National Retrovirus Reference Center, Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece. adakat@med.uoa.gr</style></auth-address></record></records></xml>